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Abstract 
Background: While antiretroviral therapies have improved life expectancy and reduced viral loads in HIV-1-positive 
individuals, the cessation of treatment results in a rebound of viral replication. This suggests that a reservoir of 
latently-infected cells remains within these patients, the identity of which is ill-defined and therefore difficult to target 
therapeutically. Current strategies are aimed at using drugs such as histone deacetylase (HDAC) inhibitors to induce 
the expression of latent HIV-1 proviruses in order to activate and ultimately eradicate this reservoir of infected cells. 
One concern with the use of HDAC inhibitors is that they could up-regulate human endogenous retroviruses (HERVs), 
as well as HIV-1, with potentially pathophysiological consequences.
Results: In this study, we analysed the transcription of HERV genes in HIV-1 latency T cell (J-LAT 8.4) and monocyte 
(U1) models following treatment with the HDAC inhibitors, vorinostat, panobinostat and romidepsin. We examined 
the expression of HERV-K (HML-2) env and pol, as well as the co-opted genes HERV-W env (syncytin-1), HERV-FRD env 
(syncytin-2), in these cell lines. Finally, we investigated HERV expression in primary human T cells.
Conclusions: We show that HDAC inhibitors did not substantially increase the transcription of the analysed HERV env 
or pol genes, suggesting that histone acetylation is not crucial for controlling HERV expression in these experimental 
models and in ex vivo primary human T cells. Importantly, this indicates that unwanted HERV expression does not 
appear to be a barrier to the use of HDAC inhibitors in HIV-1 cure strategies.
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Background
The treatment of HIV-1-infected individuals with antiret-
roviral therapy (ART) has reduced HIV-1 associated 
morbidity and improved life expectancy [29]. Despite 
this, a persisting reservoir of latently-infected cells is the 
source of rebound in plasma viremia following cessation 
of ART [8]. An important goal in strategies to cure HIV-1 
infection is the depletion of this viral reservoir [8]. One 
cure approach—‘shock and kill’ [10]—involves first reac-
tivating viral replication and then targeting the infected 
cells for destruction.
Reactivation of latent HIV-1 has been demonstrated 
with histone deacetylase (HDAC) inhibitors in clinical 
trials [4, 5, 13, 28]. The removal of acetyl groups from 
histones by HDACs leads to transcriptional repression; 
inhibition of these enzymes is therefore thought to favour 
gene expression [34]. Vorinostat and panobinostat are 
hydroxamic acids that bind to zinc, preventing its use 
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by the zinc-dependent HDACs [29], while romidepsin 
is activated in vivo to produce a zinc-binding thiol [35]. 
In addition, the use of protein kinase C (PKC) activators, 
such as phorbol 12-myristate 13-acetate (PMA), has been 
found to induce HIV-1 expression, via nuclear factor κB 
(NF-κB) and specificity protein (Sp) transcription factor 
activation [1].
Given the effect of these agents on HIV-1 provirus 
expression, we considered whether they could also pro-
mote the expression of human endogenous retrovi-
ruses (HERVs). Expression is most likely to be relevant 
and important for intact HERV genes, which would 
then result in potential health risks as a result of pro-
tein activity or an active retroviral replication cycle [24]. 
HERV-K (HML-2) (HK2) is the most recently active 
family [26] with intact open reading frames and tran-
scription enhancers within intact long terminal repeats 
(LTRs). Moreover, two HERV env genes (HERV-W env 
and HERV-FRD env) have been co-opted by the host 
and encode proteins (syncytin-1 and syncytin-2, respec-
tively) that are critical for placentation and foetal immu-
notolerance [12]. We thus designed quantitative RT-PCR 
assays using molecular beacon probes to HK2 env and pol 
genes, as well as the co-opted HERV-W and HERV-FRD 
env genes (Additional file 1: Table S1).
Crucially, HK2 has been shown to be up-regulated by 
HIV-1 infection [6, 15] as a result of Tat activation of the 
NF-κB and nuclear factor of activated T cells (NF-AT) 
transcription factors, which then act on the HERV LTR 
promoters [16]. Thus, we hypothesise that the reactiva-
tion of HIV-1 by HDAC inhibitor treatment could have 
an indirect effect on HERV expression due to Tat. This 
indirect effect could be in addition to the potential direct 
effect of the HDAC inhibitors on HERV expression. The 
combined direct and indirect effect of HDAC inhibitors 
could, in theory, lead to an overdrive of HERV activity 
with potential health risks (e.g. due to genomic instabil-
ity [7, 24]. We therefore measured the combined direct 
and indirect effect of HDAC inhibitors on HERV expres-
sion in J-LAT8.4 and U1 cells, which are models of HIV-1 
latency in cell types that are subject to HIV-1 infection 
in vivo.
Here, we measured the expression of four HERV tar-
gets in cell lines, as well as in primary human T cells. We 
did not detect substantial up-regulation of HERV tran-
scription, suggesting that the HDACs are not critically 
involved in controlling HERV expression.
Results and discussion
HDAC inhibitors increase H4 acetylation
To determine if the HDAC inhibitors were functional, 
total cellular extracts of U1s treated with the inhibitors 
were analysed by western blotting for acetylated histone 
H4. The cells were either left untreated or treated with 
vorinostat (1  μM), panobinostat (0.1  μM), romidepsin 
(0.2 μM), prostratin (1 μM) or PMA (100 ng/mL) for 24 h. 
Treatment with the HDAC inhibitors showed an increase 
in histone H4 acetylation compared to the untreated 
control (Fig. 1a). The protein kinase C (PKC) activators, 
PMA and prostratin, did not induce histone acetylation 
as expected. Importantly, PMA was also tested on the 
human monocytic cell line, THP1s, and found to induce 
differentiation into macrophages, resulting in altered 
morphology (more granular cytoplasm and larger nuclei) 
and in the cells becoming adherent (data not shown). In 
addition, HDAC inhibitors induced HIV-1 p24 expres-
sion in U1s, as measured by FACS (Fig.  1b). Thus, the 
HDAC inhibitors were biologically active in the cell types 
used.
The HDAC inhibitors vorinostat and panobinostat do not 
increase HERV expression in J‑LAT8.4 or U1 cells
We first assessed the relative expression of HERVs in the 
T-cell latency model, J-Lat 8.4, using the hydroxamic 
acids, vorinostat and panobinostat, as well as PMA 
(Fig.  2). The cells were treated with 1  μM vorinostat, 
0.1 μM panobinostat or 100 ng/mL PMA for 24 h, then 
harvested and the RNA extracted. Following rigor-
ous gDNA removal, the RNA was subject to two-step 
RT-qPCR.
The expression of HK2 env and pol as well as the syn-
cytins in untreated J-Lat 8.4 cells was much lower than 
the expression of the housekeeping gene (GAPDH) and 
had a range of at least 1-log. More specifically, the expres-
sion of HK2 env, HK2 pol, HERV FRD and HERV-W was 
2–3 logs lower, 2–5 logs lower, 3–4 logs lower and 3–5 
logs lower than GAPDH, respectively. Thus, if HDAC 
inhibitors were to substantially up-regulate (“resurrect”) 
HERVs, we would expect to see a substantial change of 
their expression reducing the gap between their expres-
sion and GAPDH by at least 1-log (i.e. at least more than 
the naturally occurring range).
The expression of HK2 env and pol were not signifi-
cantly increased by either vorinostat or panobinostat, 
with the mean in each case being equal to that of the 
untreated samples (represented by the dotted horizontal 
line on the graphs). Panobinostat could increase HK2 env 
expression up to a maximum of fivefold but the major-
ity of samples had values <2-fold. HK2 pol expression 
was increased by a maximum of fourfold, again with the 
majority of the samples <2-fold. For both HK2 env and 
HK2 pol, vorinostat did not induce expression above 
untreated in most samples; a few samples showed expres-
sion between 1- and 4-fold compared to untreated. This 
variability of the fold expression likely reflects the low 
copy numbers of HERV RNA. In contrast, PMA induced 
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HK2 env expression up to ninefold and HK2 pol expres-
sion up to 15-fold. By comparison, vorinostat increased 
HIV-1 expression in CD4+ T-cells by 4.8-fold [2].
Similarly, the expression of the co-opted genes, 
HERV-W env and HERV-FRD env, was not substantially 
increased by panobinostat or vorinostat. The mean values 
are between 1 and 1.7-fold, with most of the individual 
samples <2-fold. PMA variably induced the expression of 
both HERV-W env and HERV-FRD env up to a maximum 
of 6- and 10-fold, respectively, compared to the untreated 
samples (Fig. 2).
Next, we treated the monocytic latency model, U1s, 
with vorinostat, panobinostat and PMA. While panobi-
nostat variably induced HK2 env expression, the mean 
was 1.5-fold (Fig.  3, top panel). Vorinostat did not sub-
stantially induce HK2 env expression and the mean 
for the samples was the same as untreated (Fig.  3). 
HK2 pol expression was increased up to threefold with 
Fig. 1 The HDAC inhibitors promote histone acetylation and HIV-1 p24 expression. a Treatment of U1 cells with HDAC inhibitors results in increased 
acetylation of histone H4. The blot was probed with antibody to acetylated H4, followed by HRP-conjugated secondary antibody and enhanced 
chemiluminescence (ECL) detection. Subsequently, the same blots were reprobed with anti-β-actin antibody. The lanes are (1) untreated, (2) 
vorinostat, (3) panobinostat, (4) romidepsin, (5) prostratin and (6) PMA. b HIV-1 p24 expression is induced by vorinostat, panobinostat, romidepsin, 
prostratin and PMA, as measured by flow cytometry
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panobinostat treatment in one experiment but was typi-
cally increased by 1.5-fold or less. Likewise, vorinostat 
induced HK2 pol expression up to threefold, with a mean 
of <1; there was one sample that gave up to sevenfold 
induction but this is likely an outlier given the much 
lower expression level in the other samples (Fig.  3, top 
right panel). On the other hand, PMA treatment induced 
the expression of HK2 env by up to 4-fold and HK2 pol up 
to 4.5-fold. The expression of HERV-W env and HERV-
FRD env were not induced by vorinostat, panobinostat or 
PMA (Fig. 3, bottom panels).
We also treated the U1s with IL-1β since they are 
monocyte-derived and should respond via the activa-
tion of IL-1 receptor (IL-1R)-mediated NF-κB induction. 
We did so in order to examine if NF-κB activation could 
induce HERV expression, based on reports that HERVs 
could have κB response elements in their LTRs [25] and 
that murine ERVs are responsive to NF-κB following BCR 
activation [36]. However, IL-1β (10  pg/mL) treatment 
only induced expression of HK2 env and pol (Fig. 3, top 
panels) up to twofold compared to the untreated sam-
ples (statistically non-significant). IL-1β did not increase 
the expression of either HERV-W env or HERV-FRD env 
(Fig. 3, bottom panels); in fact, the overall trend suggests 
that IL-1β downregulates HERV-W and HERV-FRD env 
expression (though statistically non-significant).
Higher concentrations of the HDAC inhibitors do not 
up‑regulate HERV expression
We next considered whether the concentration of the 
HDAC inhibitors that we used were too low to induce 
HERV expression. In the experiments described so far, 
we have used vorinostat at 1  μM and panobinostat at 
0.1  μM, both within the range of concentrations shown 
to induce HIV-1 expression in cell lines or primary cells 
[28, 33]. We scaled up the concentrations to examine 
whether a much higher dose would induce HERV expres-
sion. We treated the U1 cells with 1  mM vorinostat or 
0.05  mM panobinostat, which represent 1000- or 500-
fold higher concentrations compared to those in Figs.  2 
and 3, respectively. We noticed a marked level of cell tox-
icity at these higher doses, with up to a twofold reduc-
tion in viable cells after 5 h incubation with either drug 
compared to untreated cells (data not shown); for this 
reason, we analysed the RNA from the cells after 5  h 
rather than 24  h. The short time period of this incuba-
tion may limit the detection of changes in HERV expres-
sion. However, it has been found that nuc1 nucleosome 
remodelling following vorinostat treatment for 2 h could 
occur in as little as 3 h post-treatment [13]. Along with 
acetylation, nuc1 remodelling is an essential precursor 
to HIV-1 expression. Further, studies in human primary 
cells showed vorinostat-induced HIV-1 expression fol-
lowing a 3–6 h of treatment [4].
Despite the higher doses, relative HK2 env expres-
sion did not substantially increase with either vorinostat 
or panobinostat (Fig.  4, top left). HK2 pol expression 
increased by up to threefold (statistically non-significant) 
with vorinostat but not with panobinostat (Fig.  4, top 
right). The expression of the co-opted genes, were not 
increased by treatment with vorinostat or panobinostat; 
strangely, HERV-W env appears to be down-regulated 
by panobinostat (Fig. 4, bottom panels). Thus, the higher 
doses of the HDAC inhibitors did not remarkably induce 
HERV expression in the U1s.
We also considered other classes of HDAC inhibitors, 
such as the depsipeptide romidepsin. Further, we exam-
ined the effect of a different PKC activator, prostratin. 
Both romidepsin (200  nM) and prostratin (1  μM) were 
examined for their effect on HERV expression in U1s. In 
all experiments, the expression of none of the HERVs was 
increased by either romidepsin or prostratin (Fig. 5).
Overall, the treatment of U1 or J-LAT 8.4 cells with the 
HDAC inhibitors did not result in significant increases 
in HERV expression. Doses of the drugs within the range 









































Fig. 2 The HDAC inhibitors panobinostat and vorinostat do not 
increase HERV expression in J-LAT-8.4 cells. The HERVs analysed were: 
HK2 env, HK2 pol, HERV-W env (syncytin-1) and HERV-FRD env (syncy-
tin-2). The fold change in HERV expression following drug treatment 
was compared to the untreated control (lines show 95 % CI) and was 
calculated relative to GAPDH expression. The doses of the drugs used 
were vorinostat (1 μM/well), panobinostat (0.1 μM/well), PMA (0.1 μg/
μL). The data points (empty circles) represent the relative fold change 
in expression normalised with GAPDH (black squares show the 
median and orange lines show 95 % CI) for up to three replicates in 
four independent experiments. A significant change of expression (i.e. 
higher than the untreated cells) would show the 95 % CI to be higher 
than and not overlap the dashed horizontal line which indicates 1× 
relative fold change (two-sided test)
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Fig. 3 The HDAC inhibitors panobinostat and vorinostat do not increase HERV expression in U1 cells. The HERVs analysed were: HK2 env, HK2 
pol, HERV-W env (syncytin-1) and HERV-FRD env (syncytin-2). The fold change in HERV expression following drug treatment was compared to the 
untreated control (lines show 95 % CI) and was calculated relative to GAPDH expression. The doses of the drugs used were vorinostat (1 μM/well), 
panobinostat (0.1 μM/well), PMA (0.1 μg/μL) and IL-1β (10 pg/mL). The data points represent the relative fold change in expression normalised with 
GAPDH (lines show 95 % CI) for up to three replicates (lines show 95 % CI) in four independent experiments. A significant change of expression (i.e. 
higher than the untreated cells) would show the 95 % CI to be higher than and not overlap the dashed horizontal line which indicates 1× relative 











































Fig. 4 The HDAC inhibitors panobinostat and vorinostat do not increase HERV expression in U1 cells following treatment with higher doses of the 
drugs for 5 h. The doses of the drugs used in this experiments were: vorinostat 1 μM/well, panobinostat 0.1 μM/well and PMA 0.1 μg/μL. The HERVs 
analysed were: HK2 env, HK2 pol, HERV-W env (syncytin-1) and HERV-FRD env (syncytin-2). The fold change in HERV expression following drug treat-
ment was compared to the untreated control (lines show 95 % CI) and was calculated relative to GAPDH expression. The data points represent the 
relative fold change in expression normalised with GAPDH (lines show 95 % CI) for up to three replicates in two independent experiments. A signifi-
cant change of expression (i.e. higher than the untreated cells) would show the 95 % CI to be higher than and not overlap the dashed horizontal line 
which indicates 1× relative fold change (two-sided test)
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cell lines [28, 33] were used to treat the cells for up to 24 h 
but they did not substantially increase HERV expression. 
Treatment of the cells with significantly higher doses of 
the drugs did not increase the expression of the HERVs 
after 5 h.
We next analysed expression of HERVs in uninfected 
or HIV-1-infected primary CD4+ T cells from three 
individual donors with or without panobinostat treat-
ment. These cells were completely negative for HERV-
W env and HERV-FRD env expression. HK2 env was 
negative for all conditions in all donors, with the excep-
tion of HIV-1 infected cells treated with panobinostat 
in donor 1 (Table 1). Likewise in donor 1, HK2 pol was 
negative in all but the HIV-1-infected cells treated with 
panobinostat. In contrast, donors 2 and 3 showed a basal 
level of HK2 pol expression in uninfected cells, which 
was reduced following panobinostat treatment. Like-
wise, HK2 pol was expressed following HIV-1 infection 
in donors 2 and 3 and this was reduced by panobinostat 
treatment. For donor 3, the HIV-1-infected cells showed 
similar levels of HK2 pol expression to the uninfected 
cells; thus, in this individual, HIV-1 expression alone did 
not induce HK2 pol. In combination, HIV-1 infection 
and panobinostat treatment resulted in a suppression of 
HK2 pol expression, rather than a synergistic effect as we 
had hypothesised. Overall, the results in primary cells 
shows undetectable or low levels of the HERVs measured, 
with the exception of HK2 pol expression in one donor. 
There is donor-to-donor variability, which could be clini-
cally important; some patients could exhibit enhanced 
HERV expression in response to reactivation of latent 
HIV-1 and/or HDAC inhibitor treatment and screening 
for this could be considered. Thus, the results observed 
in the cell lines are supported by the findings in primary 
cells since treatment with panobinostat did not enhance 
HERV expression; indeed, it appears to suppress HK2 pol 
expression.
It has been reported that HDAC inhibition affects gene 
expression in 2–20 % of genes [29]. Thus, other mecha-
nisms than histone acetylation/deacetylation regulate 
HERV expression. The class I HDACs 1, 2 and 3 have 
been shown to localise to HIV-1 proviruses using chro-
matin immunoprecipitation (ChIP) [22], which explains 
why HDAC inhibition can alter HIV-1 expression. Other 
studies have shown that a number of transcription factors 
recruit HDACs to the HIV-1 LTR and thereby contribute 
to latency [9, 18]. In contrast, few studies have looked at 
the interaction of HDACs with HERV LTRs. One study 
used ChIP to show that histone H3 acetylation was criti-
cal to the expression of HERV-W and HERV-FRD env in 
placental tissues, where they are known to have biological 
roles [30]. However, in non-placental tissues transcrip-
tion is suppressed by histone H3 methylation and ineffi-













































Fig. 5 Romidepsin and Prostratin do not increase HERV expression in U1s. The HERVs analysed were: HK2 env, HK2 pol, HERV-W env (syncytin-1) and 
HERV-FRD env (syncytin-2). The fold change in HERV expression following drug treatment was compared to the untreated control (lines show 95 % 
CI) and was calculated relative to GAPDH expression. Romidepsin and prostratin were used at final concentrations of 0.2 and 1 μM, respectively. The 
data points represent the relative fold change in expression normalised with GAPDH (lines show 95 % CI) in two independent experiments. A sig-
nificant change of expression (i.e. higher than the untreated cells) would show the 95 % CI to be higher than and not overlap the dashed horizontal 
line which indicates 1× relative fold change (two-sided test)
Table 1 HERV expression in primary human T cells
Values given are copies of the HERV target per 1000 copies of GAPDH
Target Treatment Donor 1 Donor 2 Donor 3
HK2 pol Uninfected 0 7.8 3952
Uninfected + panobinostat 0 5.4 0
HIV-1 0 186 3783
HIV-1 + panobinostat 21 21 309
HK2 env Uninfected 0 0 0
Uninfected + panobinostat 0 0 0
HIV-1 0 0 0
HIV-1 + panobinostat 117 0 0
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in a placental cell line but not in HeLa cells, correspond-
ing to transcriptional activation in the placenta but 
suppression elsewhere. The study by Trejbalová and col-
leagues highlights the fact that there could be tissue-spe-
cific mechanisms of control of HERV expression. Further 
to this, and because increased HERV expression has been 
described in several types of cancer [11], it would be of 
interest to examine HERV expression following HDAC 
inhibitor treatment of a panel of uninfected human cell 
types. Control of HERV transcription by other mecha-
nisms than acetylation has been described, including 
CpG methylation of HK2 [23]. It is thus possible that the 
inhibition of HDACs by the hydroxamic acids (vorinostat 
and panobinostat) or romidepsin has no remarkable 
effect on HERV expression because either these HDACs 
are not biologically relevant to the control of HERV tran-
scription or there are additional mechanisms on top of 
HDACs to control HERV transcription.
One aspect of the study we would like thus to explore 
further is the effect of combination treatments. Pros-
tratin, a PKC activator, activates HIV-1 in a synergistic 
manner when used in conjunction with a HDAC inhibi-
tor [29]. Prostratin itself causes nuclear accumulation of 
the NF-κB p65-p50 heterodimer, the activity of which is 
inhibited by deacetylation of the p65 subunit by HDAC3 
[29]. Inhibition of HDAC3 activity thus permits the acet-
ylation and hyperactivation of NF-κB and the reactiva-
tion of HIV-1 from latency [29].
Conclusions
A key objective of this study was to evaluate HERV 
expression following treatment with the HDAC inhibi-
tors. Given the use of these drugs in the treatment of 
certain cancers and the reactivation of latent HIV-1, 
it is important to consider whether the HERVs are also 
reactivated. We have previously shown that ERV activ-
ity has been suppressed by body size throughout evolu-
tion, probably due to higher cancer burden [21], and so 
increased HERV expression could be detrimental. For 
example, increased HERV-K expression was detected 
in germ cell and trophoblastic tumours [17], melanoma 
cells [27], as well as in the blood of breast cancer [32] 
and prostate cancer patients [31]. However, whether 
the expression of HERVs drive tumorigenesis or are the 
result of the aberrant gene expression in cancers is still 
undetermined [11]. Further, HERV proteins are not 
normally detected in healthy human tissues but were 
detectable following HIV-1 infection in primary human 
donor cells [19]. Importantly, we do not observe remark-
ably increased expression of the HERVs with the HDAC 
inhibitors vorinostat, panobinostat or romidepsin in the 
context of HIV-1 infection nor in uninfected cells. Other 
safety concerns, such as the toxicity and mutagenicity of 
vorinostat [29] remain to be addressed. Finally, our stud-
ies have been conducted in cell lines, which have limita-
tions due to being immortalised, clonal cell populations 
[3]. While these cells might not recapitulate the biology of 
HIV-1 latency, we have found similar results in primary T 
cells, suggesting that HDAC inhibitor treatment of HIV-
1-infected cells does not lead to a synergistic increase in 
HERV expression. It will be important to study HERV 
expression in the context of clinical trials such as RIVER 
(Research in Viral Eradication of HIV Reservoirs), which 
employs a ‘kick and kill’ strategy with vorinostat treat-
ment and two different anti-HIV-1 vaccines.
Methods
HDAC inhibitors, protein kinase C activators and cytokines
Vorinostat was purchased from Sigma-Aldrich (Poole, 
UK) and panobinostat was ordered from Cambridge 
Bioscience (Cambridge, UK). They were each reconsti-
tuted in sterile DMSO (Sigma-Aldrich) to a concentra-
tion of 20 mM. Romidepsin was purchased from Abcam 
(Cambridge, UK) and reconstituted at a concentration 
of 2 mM in DMSO. Prostratin was obtained from Cam-
bridge Bioscience.
Phorbol 12-myristate 13-acetate (PMA) was purchased 
from Abcam and reconstituted with DMSO at a concen-
tration of 1  mg/mL. Recombinant interleukin-1β (IL-
1β) was purchased from Life Technologies (Paisley, UK) 
and reconstituted at a concentration of 1 μg/mL in pure 
dH2O.
Cell culture and drug treatments
The following reagents were obtained through the 
AIDS Reagent Program, Division of AIDS, NIAID, 
NIH: J-Lat 8.4 cells from Dr. Eric Verdin and U1 cells 
from Dr. Thomas Folks. More specifically, the J-LAT8.4 
cell line is a clone of Jurkat T cells containing one full-
length HIV-1 provirus with the green fluorescent pro-
tein (GFP) sequence in place of nef and a frameshift 
mutation in the env gene [20]. The expression of HIV-1 
is low to undetectable in this cell line in the absence of 
tumour necrosis factor alpha (TNFα) [20]. U1 cells were 
derived from the promonocytic cell line U937 which 
were chronically infected with HIV-1 and show limited 
constitutive activation of HIV-1; recombinant granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) 
was able to induce expression of HIV-1 in these cells 
[14]. U1s were examined using restriction enzymes and 
found to contain two copies of HIV-1 proviral DNA 
[14].
The cells were cultured in RPMI supplemented with 
10 % FBS, 1 % penicillin–streptomycin and 2 mM l-glu-
tamine, all of which were purchased from Sigma-Aldrich. 
The cells were passaged twice per week at a ratio of 1:5. 
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To test the HDAC inhibitors, the cells were seeded at a 
density of 5 × 105 cells/well in a 96 well plate.
Unstimulated human primary CD4+ T cells were iso-
lated from PBMCs from three separate donors. The cells 
were either left uninfected or infected with the ×4 tropic 
LAI strain. For infection, cells were spinoculated for 2 h 
at 1200  g with viral supernatant, after which the cells 
were washed twice with supplemented RPMI media and 
cultured for 48 h in the presence of 1.25 μM saquinavir to 
prevent spreading infection. After culturing both unin-
fected and infected cells for 48 h, the cells were either left 
untreated or treated with 20 nM panobinostat for a fur-
ther 24 h.
RNA extraction
The cells were lysed using QIAgen RNeasy kit Buffer RLT 
and then homogenized using a QIAshredder column. 
The RNeasy RNA extraction procedure was then fol-
lowed according to the manufacturer’s protocol (Qiagen, 
Manchester, UK).
Removal of genomic DNA
Since there are many copies of HERVs in the genome (for 
example around 100 almost full-length copies of HK2), it 
was essential to remove all genomic DNA (gDNA) from 
the samples. To do so, we used the Turbo DNA-free kit 
from Life Technologies. Briefly, we treated 10μL of RNA 
(equal to 1/4.5 of the total extract) with 1  μL DNase 
and 1.2 μL of the DNase buffer. Next, we incubated the 
samples at 37 °C for 30 min. We then added 2 μL of the 
inactivating agent and incubated the samples at 70  °C 
for 10 min to completely inactivate the DNase (with the 
inactivating reagent and heat-treatment), as well as pro-
tect the RNA from divalent cations (with the inactivating 
reagent). We pelleted the inactivation agent by centrifu-
gation and the supernatant was reserved as the pure RNA 
fraction.
We first validated that gDNA was totally removed by 
negative SYBR green qPCR as well as by negative agarose 
gel analysis (using HK2 pol primers). We also evaluated 
that the removal of inactivating reagent and that the inac-
tivation of DNase was complete by spiking the samples 
with 105 copies of our standards and then doing RT-
qPCR using a Roche Lightcycler Nano. Quantitative cycle 
(Cq) values were as high as expected (data not shown) 
suggesting that no PCR inhibition occurred due to rem-
nants of the inactivation reagent, but also that DNase 
activity was no longer present. To evaluate RNA degra-
dation due to the DNase treatments, we also performed 
two sequential DNase treatments, followed by the inacti-
vation step, and then re-evaluated the RNA in RT-qPCR. 
Cq values after one and two treatments were comparable 
suggesting that RNA was not degraded throughout the 
process.
Finally, we diluted the extracted total RNA in either 
pure or DNase-treated water (1:1 dilution), followed by 
RT-qPCR and comparing the Cq values. We did this to 
test if removal of divalent cations in the DNase inactiva-
tion process was incomplete which would then degrade 
RNA at high temperature or inhibit reverse transcription. 
This test also evaluates if removal of DNase is incomplete 
which could degrade the newly formed cDNA. Cq values 
in the samples diluted with either DNase-treated water 
or pure water samples were comparable, suggesting that 
if RNA or cDNA degradation has occurred, it was not 
detectable.
Reverse transcription
We used Superscript III reverse transcriptase (Life Tech-
nologies) and random hexamers (Bioline, London UK) to 
reverse transcribe the gDNA-free RNA in a final volume 
of 20  µL. In parallel, we performed identical reactions 
lacking the reverse transcriptase (no RT control). The 
resulting cDNA or no RT control (2.5 µL) were then used 
in qPCR with Platinum Taq (Life Technologies) in a cus-
tom 50 µL master mix. We purchased additional 50 mM 
MgCl2 from Bioline and the deoxynucleotide triphos-
phate set was purchased from Sigma-Aldrich. The use of 
the no RT control provided additional assurance that the 
gDNA had been removed.
Quantitative PCR
HERVs have multiple copies in the genome, thus con-
ventional PCR (i.e. without probes) might amplify non-
specific targets, such as from older non-functional 
integrations. In order to measure the recently active 
clade of HK2 and the co-opted copies of HERV-W and 
HERV-FRD, we designed primers and Molecular Bea-
cons probes using Beacon Designer software (Premier 
Bio-Soft) and had the oligos and probes synthesized by 
Sigma-Aldrich. We designed primers and 6-Fam-labelled 
Molecular Beacon probes to HK2 (env, pol), HERV-
FRD (env) and HERV-W (env), as well as GAPDH prim-
ers and a HEX-labelled Molecular Beacon probe for 
use as a housekeeping reference gene (Additional file  1: 
Table S1). We evaluated that the beacons were properly 
designed through melting curve analyses. We produced 
DNA standards by PCR using the specific primer sets 
and a commercial gDNA stock. The resulting PCR ampli-
cons were gel-extracted, purified and verified by Sanger 
sequencing, then they were quantified with the Quant-
iT™ PicoGreen® dsDNA Assay Kit (Thermo Fisher 
Scientific), serially diluted and used to construct stand-
ard curves from 1 to 106 copies/reaction. We included 
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standards in each qPCR reaction as controls and to eval-
uate the sensitivity of the reaction.
Further, to ensure that our results were not biased by 
possible effects of the drugs on GAPDH, we evaluated the 
cDNA with two other housekeeping genes. The human 
endogenous control kits for glucoronidase (GUSB) and 
18S rRNA were purchased from Life Technologies. The 
correlations between GAPDH and GUSB or GAPDH 
and 18S rRNA were very strong (R2 = 0.94 or R2 = 0.89, 
respectively), suggesting that the normalisation using 
GAPDH was relatively unbiased.
Acetylated histone H4
We seeded J-Lat 8.4 or U1 cells at a density of 1 ×  106 
cells/well in 6-well plates. The following day, we treated 
cells with the HDAC inhibitors. The cells were harvested 
24 h later by centrifugation and the pellets were washed 
once with PBS. We then lysed the cells in lysis buffer 
(137  mM NaCl, 20  mM Tris–HCl, 1  mM EDTA, 0.5  % 
Triton-X 100) supplemented with protease inhibitor cock-
tail and N-octylglucoside on ice for 30 min. Subsequently, 
we centrifuged the lysates for 10 min at 10,000g to pellet 
the nuclei and the supernatant was reserved for analysis. 
SDS-containing sample buffer was added to the lysate to a 
final concentration of 1×. Next, we boiled the samples for 
5 min, chilled them on ice and centrifuged briefly.
We then analysed the samples by discontinuous SDS-
PAGE (12  % resolving gel), followed by transfer for 
45 min at 100 V onto 0.22 μM PVDF. The membrane was 
blocked in Starting Block reagent (Thermo Scientific, 
Basingstoke, UK), which was also used as the antibody 
diluent. We used a rabbit polyclonal antibody to acety-
lated histone H4 from Santa Cruz Biotechnology Inc. 
(Insight Biotechnology, Wembley, UK), at a concentra-
tion of 1/1000 in the diluent. The blots were incubated 
overnight in primary antibody at room temperature with 
constant rocking. The next day, we washed the blots three 
times in PBS with 0.05 % Tween 20 (Fisher Scientific). We 
then added the secondary anti-rabbit-HRP antibody at 
a 1/4000 dilution for 1 h at room temperature. The blot 
was then washed twice with PBS-Tween and once with 
PBS alone. We then developed the blot using using Novex 
ECL and visualised using the Syngene G:box system. The 
blot was subsequently reprobed with a rabbit polyclonal 
antibody to β-actin (Santa Cruz Biotechnology Inc.) at a 
concentration of 1/1000 to show equal loading.
Intracellular p24 staining
For intracellular p24 staining, cells were first stained with 
the LIVE/DEAD fixable near-IR dead cell stain kit (Life 
Technologies) as per the manufacturer’s protocol, then 
fixed with 2 % paraformaldehyde for 30 min. Cells were 
subsequently washed and then simultaneously permeabi-
lised with 0.05 % saponin and stained using the KC57 PE 
antibody (Beckman Coulter) for 40 min. HIV-1 p24 levels 
were then measured by flow cytometry.
Calculation of the Mean and 95 % Confidence Intervals (CI) 
of the gene expression
The fold change of expression is a positive real num-
ber, with asymmetric long-tailed distribution, which we 
assume follows a log-normal distribution. We log-trans-
form the fold change and calculate the 95 % CI of the log-
transformed mean according to a normal distribution. 
Each cell-culture experiment had numerous replicates 
(2 or 3) and was repeated multiple times (up to 5). Thus 
to calculate the variance of the mean, we do not pool all 
the replicates from different cell culture experiments, but 
instead we calculate the variance for each experiment 
and then combine the variance metrics as follows: sup-
pose we have two experiments containing n1 and n2 rep-
licates with means X1 and X2, and variances S21 and S22. If 
Xc is the combined mean and S2c  is the combined vari-
ance of n1 + n2 replicates, then the combined variance is 
given by:
and
The confidence interval of the log-transformed values 








 is the standard 
error of the log-transformed mean and ne is the number 
of the individual cell culture experiments.
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